BsUFA IV: Fiscal Years 2028-2032

Why It Matters

Securing BsUFA IV funding ensures the FDA can maintain a predictable, efficient biosimilar review pathway, critical for expanding affordable biologic options. Delays could stall market entry and increase costs for patients and manufacturers.

Key Takeaways

• BsUFA IV targets fiscal years 2028‑2032
• Public kickoff meeting held Dec 3, 2025
• FDA will consult industry, patient advocates for enhancements
• Reauthorization needed before BsUFA III expires Sep 2027

Pulse Analysis

The Biosimilar User Fee Act (BsUFA) is the primary mechanism by which the FDA funds the review of biosimilar products. First enacted in 2012, the act has been reauthorized every five years, providing a predictable budget stream that supports staffing, technology, and review timelines. By linking fees to the volume of biosimilar submissions, BsUFA aligns regulatory capacity with market demand, helping to lower the cost of biologic therapies for U.S. patients.

On December 3, 2025, the FDA convened a public meeting to launch the BsUFA IV reauthorization process for fiscal years 2028‑2032. The meeting outlined the agency’s intent to modernize fee structures, improve review efficiency, and incorporate stakeholder feedback. Industry participants, patient advocacy groups, and consumer representatives are slated to contribute to draft proposals, with the goal of addressing emerging challenges such as complex manufacturing pathways and the need for faster approvals.

The upcoming reauthorization carries significant strategic implications. Without timely legislation, the FDA would lose a critical funding source after BsUFA III expires in September 2027, potentially slowing biosimilar approvals and raising development costs. Companies planning pipeline launches must monitor fee adjustments and compliance requirements closely. Moreover, a well‑designed BsUFA IV could accelerate market entry, increase competition, and drive down prices, reinforcing the broader policy objective of expanding affordable biologic access in the United States.